Emilia BiaÅ, opiotrowicz

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6827884/publications.pdf

Version: 2024-02-01

759233 794594 30 380 12 19 g-index citations h-index papers 30 30 30 809 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	IDH2 mutations in patients with normal karyotype AML predict favorable responses to daunorubicin, cytarabine and cladribine regimen. Scientific Reports, 2021, 11, 10017.	3.3	3
2	Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. Cancer Research, 2021, 81, 6029-6043.	0.9	20
3	DEPTOR is a microRNA-155 target regulating migration and cytokine production in diffuse large B-cell lymphoma cells. Experimental Hematology, 2020, 88, 56-67.e2.	0.4	7
4	SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism. Cell Death and Disease, 2020, 11, 956.	6.3	20
5	Serine Biosynthesis Pathway Supports MYC–miR-494–EZH2 Feed-Forward Circuit Necessary to Maintain Metabolic and Epigenetic Reprogramming of Burkitt Lymphoma Cells. Cancers, 2020, 12, 580.	3.7	33
6	SIRT1 and HSP90alpha Are Functionally Linked and Control Mitotic Chromosome Segregation and Cell Viability in a Subset of Dlbcls. Blood, 2020, 136, 28-29.	1.4	1
7	Hodgkin Lymphoma Reed-Sternberg Cells Induce Immunosuppressive and Pro-Angiogenic Phenotype of Tumor-Associated Macrophages in a Paracrine Manner. Blood, 2020, 136, 30-30.	1.4	O
8	Inhibition of PIM Kinases in Diffuse Large B-Cell Lymphoma Cells Targets MYC-Dependent Transcriptional Program, Increases CD20 Expression and Augments the Efficacy of Anti-CD20 Antibodies. Blood, 2020, 136, 33-34.	1.4	0
9	Microenvironmentâ€induced PIM kinases promote CXCR 4â€triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration. Journal of Cellular and Molecular Medicine, 2018, 22, 3548-3559.	3.6	17
10	Zaburzenia mechanizmów epigenetycznych w ostrej biaÅ,aczce szpikowej. Hematologia, 2018, 9, 100-109.	0.0	0
11	Expression of PIM kinases in Reed-Sternberg cells fosters immune privilege and tumor cell survival in Hodgkin lymphoma. Blood, 2017, 130, 1418-1429.	1.4	42
12	MiR-17-92 represses PTPROt and PP2A phosphatases and amplifies tonic BCR signaling in DLBCL cells. Experimental Hematology, 2017, 46, 56-61.e1.	0.4	13
13	Familial Alzheimer's Disease Lymphocytes Respond Differently Than Sporadic Cells to Oxidative Stress: Upregulated p53-p21 Signaling Linked with Presenilin 1 Mutants. Molecular Neurobiology, 2017, 54, 5683-5698.	4.0	11
14	Molekularna patogeneza przewlekÅ,ej biaÅ,aczki limfocytowej. Hematologia, 2017, 7, 273-286.	0.0	1
15	FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism. Oncogene, 2016, 35, 5989-6000.	5.9	42
16	FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas. Blood, 2016, 127, 739-748.	1.4	54
17	Microenvironment-Induced Expression of PIM Kinases Supports Chronic Lymphocytic Leukemia Cells Survival and Promotes CXCR4-mTOR Pathway Dependent Migration. Blood, 2016, 128, 3239-3239.	1.4	4
18	MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. PLoS ONE, 2016, 11, e0155893.	2.5	26

#	Article	IF	CITATIONS
19	Functional Link Between Heat Shock Protein HSP90alpha and Sirtuin 1 (SIRT1) in the Pathogenesis of Diffuse Large B Cell Lymphoma. Blood, 2016, 128, 4120-4120.	1.4	O
20	Downregulation of Deptor By MiR-155 Promotes Cell Survival through Activation of PI3K/AKT and NFkB Signaling in ABC-Type Diffuse Large B-Cell Lymphomas. Blood, 2016, 128, 1761-1761.	1.4	2
21	FOXO1-p300-Txn Circuit Regulates Oxidative Stress Responses in Diffuse Large B-Cell Lymphomas Characterized By Enhanced Oxidative Phosphorylation. Blood, 2015, 126, 466-466.	1.4	1
22	A Novel Pan-PIM Kinase Inhibitor, SEL24-B489, Induces Apoptosis and Inhibits Proliferation of Diffuse Large B-Cell Lymphoma Cells through Inhibition of Protein Translation and Attenuation of Myc and NFkB Activity. Blood, 2015, 126, 706-706.	1.4	2
23	Abstract 5394: First-in-class dual PIM/FLT3 kinase inhibitor SEL24-B489 for the treatment of hematological malignancies. Cancer Research, 2015, 75, 5394-5394.	0.9	1
24	HIF1-Alpha and MYC Transcription Factor Signatures in B-Cell Acute Lymphoblastic Leukemia Are Associated with Positive Minimal Residual Disease Status: Therapeutic Implications. Blood, 2015, 126, 1436-1436.	1.4	O
25	Expression of PIM Kinases in Reed-Sternberg Cells Fosters Immune Privilege and Tumor Cell Survival in Classical Hodgkin Lymphoma. Blood, 2015, 126, 819-819.	1.4	O
26	MEK1 Inhibitor Selumetinib Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia Cells (B-ALL) to Dexamethasone through Modulation of mTOR Activity and Stimulation of Autophagy. Blood, 2015, 126, 4917-4917.	1.4	0
27	Abstract 1749: Preclinical characterization of SEL24-B489, a dual PIM/FLT3 inhibitor for the treatment of hematological malignancies. Cancer Research, 2014, 74, 1749-1749.	0.9	2
28	Downregulation of extracellular signal-regulated kinase 1/2 activity by calmodulin KII modulates p21Cip1 levels and survival of immortalized lymphocytes from Alzheimer's disease patients. Neurobiology of Aging, 2013, 34, 1090-1100.	3.1	22
29	Highly Pathogenic Alzheimer's Disease Presenilin 1 P117R Mutation Causes a specific Increase in p53 and p21 Protein Levels and Cell Cycle Dysregulation in Human Lymphocytes. Journal of Alzheimer's Disease, 2012, 32, 397-415.	2.6	27
30	Cell cycle regulation distinguishes lymphocytes from sporadic and familial Alzheimer's disease patients. Neurobiology of Aging, 2011, 32, 2319.e13-2319.e26.	3.1	29